Stablepharma Ltd

United Kingdom
Burley, England, United Kingdom, BA1 1HE

Company profile

Stablepharma Ltd company profile

Stablepharma’s technology platform, StablevaX™ converts existing approved vaccines, therapeutics and diagnostics into fridge free thermostable products that do not require refrigeration to preserve them, thereby addressing the global challenges of the cold chain. Stablepharma’s R&D team have identified up to 60 vaccine candidates that could be suitable for StablevaX™ technology. The company actively collaborates with global vaccine manufacturers, academic institutions and NGOs, to advance their pipeline of thermostable products.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2012-01-26

Headquarters

Postal code
BA1 1HE
Country code
GB
Continent
Europe

Capital profile

Funding and company signals

Funding rounds
12
Total equity funding
$17.4M
Last funding
Grant / $2.6M / 2025-02-19
Last equity funding
Undisclosed / $4.3M
Investors
5
Lead investors
4
Founders
2
Articles
30

Founders and investors

Founders

Dr Bruce RoserNick Child

Lead investors

Ascension VenturesEuropean Innovation CouncilInnovate UKSFC Capital

Investors

Ascension VenturesEISMEAEuropean Innovation CouncilInnovate UKSFC Capital